Researchers at the University of Tsukuba have shown how mutations in the VAV1 gene may trigger T-cell neoplasia in laboratory mice. Using cutting-edge research techniques including generation of ...

Shares of Monte Rosa Therapeutics (NASDAQ:GLUE) rallied 49% Monday morning after the biotech signed an exclusive license deal with Novartis (NYSE:NVS) to advance its VAV1-directed molecular glue ...

Company to present clinical results from Phase 1 SAD/MAD study of VAV1-directed molecular glue degrader MRT-6160 and Phase 1/2 study of MRT-2359 in MYC-driven solid tumors Conference call and ...

--Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company developing novel molecular glue degrader- based medicines, today announced the closing of the Company’ s previously ...

Now, researchers at the University of Tsukuba have illustrated how mutations in a specific gene called VAV1 may promote tumors involving a type of white blood cell, the T-cell, in experimental mice.

January 2022 debuted Reshmi Parameswaran's novel B-cell activating factor (BAFF) CAR T product effective at killing multiple B-cell cancers with robust in vitro and in vivo cytotoxicity exerted by ...

Data will be presented during Poster Session A on Sunday, November 12, 2023 from 9:00-11:00 am PT BOSTON, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical ...